Jack B. Bishop
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jack B. Bishop has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Kristine L. Witt
National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
6 shared publicationsAbraham Nyska
Laboratory of Experimental Pathology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina
2 shared publicationsGrace E. Kissling
Biostatistics Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina
2 shared publicationsMichael D. Shelby
National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina
2 shared publications- Sally Darney Perreault
US EPA , Cary, NC, USA
2 shared publications Alfred F. McFee
Department of Genetics, Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee
1 shared publication
Latest Publications
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 190-200
Mitochondrial toxicity in hearts of CD‐1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination
Antiretroviral therapies based on nucleoside reverse transcriptase inhibitors (NRTIs), like zidovudine (3′‐azido‐3′‐deoxythymidine; AZT) and lamivudine ((‐)2′,3′‐dideoxy‐3′‐thiacytidine; 3TC), markedly reduce mother‐to‐child transmission of the human immunodeficiency virus (HIV). However, AZT induces damage in nuclear DNA of mice exposed in utero and postnatally, and mitochondrial DNA (mtDNA) damage has been observed in both human and mouse neonates following perinatal exposure to AZT and AZT/3TC in combination. To provide animal data modeling the NRTI‐induced heart damage reported in human infants, we treated pregnant CD‐1 mice throughout gestation and treated their pups by direct gavage from postnatal day (PND) 4 through PND 28 with daily doses of 150 mg/kg body weight (bw)/day AZT, 75 mg/kg bw/day 3TC, 125/62.5 mg/kg bw/day AZT/3TC, or the vehicle control. Half the pups were euthanized on PND 28; the remainder received no further dosing, and were euthanized at week 10. Heart tissue was collected, total DNA was extracted, and mtDNA copy number relative to nuclear DNA copy number, mtDNA damage, and mtDNA mutation assays were performed using PCR‐based methods. Analyses revealed increases in mtDNA lesions in 4‐week‐old males and females treated with AZT or 3TC, but not in 10‐week‐old mice, suggesting that the damage resolved after treatment ceased. Interestingly, 10‐week‐old females treated with AZT/3TC had significant increases in mtDNA damage. Point mutations were elevated in 10‐week‐old females treated with AZT or AZT/3TC, but not 3TC; no increases in mutations were seen in either gender at 4 weeks of age. Our data suggest that AZT/3TC combination treatment produces greater mtDNA damage than either agent individually, and that female mice are more sensitive than males to AZT/3TC‐induced mtDNA damage. Environ. Mol. Mutagen., 2006. Published 2006 Wiley‐Liss, Inc.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 190-200
Mitochondrial toxicity in hearts of CD‐1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination
Antiretroviral therapies based on nucleoside reverse transcriptase inhibitors (NRTIs), like zidovudine (3′‐azido‐3′‐deoxythymidine; AZT) and lamivudine ((‐)2′,3′‐dideoxy‐3′‐thiacytidine; 3TC), markedly reduce mother‐to‐child transmission of the human immunodeficiency virus (HIV). However, AZT induces damage in nuclear DNA of mice exposed in utero and postnatally, and mitochondrial DNA (mtDNA) damage has been observed in both human and mouse neonates following perinatal exposure to AZT and AZT/3TC in combination. To provide animal data modeling the NRTI‐induced heart damage reported in human infants, we treated pregnant CD‐1 mice throughout gestation and treated their pups by direct gavage from postnatal day (PND) 4 through PND 28 with daily doses of 150 mg/kg body weight (bw)/day AZT, 75 mg/kg bw/day 3TC, 125/62.5 mg/kg bw/day AZT/3TC, or the vehicle control. Half the pups were euthanized on PND 28; the remainder received no further dosing, and were euthanized at week 10. Heart tissue was collected, total DNA was extracted, and mtDNA copy number relative to nuclear DNA copy number, mtDNA damage, and mtDNA mutation assays were performed using PCR‐based methods. Analyses revealed increases in mtDNA lesions in 4‐week‐old males and females treated with AZT or 3TC, but not in 10‐week‐old mice, suggesting that the damage resolved after treatment ceased. Interestingly, 10‐week‐old females treated with AZT/3TC had significant increases in mtDNA damage. Point mutations were elevated in 10‐week‐old females treated with AZT or AZT/3TC, but not 3TC; no increases in mutations were seen in either gender at 4 weeks of age. Our data suggest that AZT/3TC combination treatment produces greater mtDNA damage than either agent individually, and that female mice are more sensitive than males to AZT/3TC‐induced mtDNA damage. Environ. Mol. Mutagen., 2006. Published 2006 Wiley‐Liss, Inc.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 322-329
Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother‐to‐child transmission of HIV
Zidovudine‐based antiretroviral therapies (ARTs) for treatment of HIV‐infected pregnant women have markedly reduced mother‐to‐child transmission of the human immunodeficiency virus (HIV‐1) from ∼25% to P = 0.006) and 0.12 ± 0.02 in control cord bloods (P < 0.0001). %MN‐RET in ZDV‐exposed newborns decreased over the first 6 months of life to levels comparable to cord blood controls. These results demonstrate that transplacentalZDV exposure is genotoxic in humans. Long‐term monitoring of HIV‐uninfected ZDV‐exposed infants isrecommended to ensure their continued health. Environ. Mol. Mutagen. Published 2007 Wiley‐Liss, Inc.
- 19 March 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (3-4) , 322-329
Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother‐to‐child transmission of HIV
Zidovudine‐based antiretroviral therapies (ARTs) for treatment of HIV‐infected pregnant women have markedly reduced mother‐to‐child transmission of the human immunodeficiency virus (HIV‐1) from ∼25% to P = 0.006) and 0.12 ± 0.02 in control cord bloods (P < 0.0001). %MN‐RET in ZDV‐exposed newborns decreased over the first 6 months of life to levels comparable to cord blood controls. These results demonstrate that transplacentalZDV exposure is genotoxic in humans. Long‐term monitoring of HIV‐uninfected ZDV‐exposed infants isrecommended to ensure their continued health. Environ. Mol. Mutagen. Published 2007 Wiley‐Liss, Inc.
- 15 February 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (2) , 71-95
Assessing human germ‐cell mutagenesis in the Postgenome Era: A celebration of the legacy of William Lawson (Bill) Russell
Birth defects, de novo genetic diseases, and chromosomal abnormality syndromes occur in ∼5% of all live births, and affected children suffer from a broad range of lifelong health consequences. Despite the social and medical impact of these defects, and the 8 decades of research in animal systems that have identified numerous germ‐cell mutagens, no human germ‐cell mutagen has been confirmed to date. There is now a growing consensus that the inability to detect human germ‐cell mutagens is due to technological limitations in the detection of random mutations rather than biological differences between animal and human susceptibility. A multidisciplinary workshop responding to this challenge convened at The Jackson Laboratory in Bar Harbor, Maine. The purpose of the workshop was to assess the applicability of an emerging repertoire of genomic technologies to studies of human germ‐cell mutagenesis. Workshop participants recommended large‐scale human germ‐cell mutation studies be conducted using samples from donors with high‐dose exposures, such as cancer survivors. Within this high‐risk cohort, parents and children could be evaluated for heritable changes in (a) DNA sequence and chromosomal structure, (b) repeat sequences and minisatellites, and (c) global gene expression profiles and pathways. Participants also advocated the establishment of a bio‐bank of human tissue samples from donors with well‐characterized exposure, including medical and reproductive histories. This mutational resource could support large‐scale, multiple‐endpoint studies. Additional studies could involve the examination of transgenerational effects associated with changes in imprinting and methylation patterns, nucleotide repeats, and mitochondrial DNA mutations. The further development of animal models and the integration of these with human studies are necessary to provide molecular insights into the mechanisms of germ‐cell mutations and to identify prevention strategies. Furthermore, scientific specialty groups should be convened to review and prioritize the evidence for germ‐cell mutagenicity from common environmental, occupational, medical, and lifestyle exposures. Workshop attendees agreed on the need for a full‐scale assault to address key fundamental questions in human germ‐cell environmental mutagenesis. These include, but are not limited to, the following: Do human germ‐cell mutagens exist? What are the risks to future generations? Are some parents at higher risk than others for acquiring and transmitting germ‐cell mutations? Obtaining answers to these, and other critical questions, will require strong support from relevant funding agencies, in addition to the engagement of scientists outside the fields of genomics and germ‐cell mutagenesis. Environ. Mol. Mutagen., 2007. Published 2007 Wiley‐Liss, Inc.
- 15 February 2007
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 48 (2) , 71-95
Assessing human germ‐cell mutagenesis in the Postgenome Era: A celebration of the legacy of William Lawson (Bill) Russell
Birth defects, de novo genetic diseases, and chromosomal abnormality syndromes occur in ∼5% of all live births, and affected children suffer from a broad range of lifelong health consequences. Despite the social and medical impact of these defects, and the 8 decades of research in animal systems that have identified numerous germ‐cell mutagens, no human germ‐cell mutagen has been confirmed to date. There is now a growing consensus that the inability to detect human germ‐cell mutagens is due to technological limitations in the detection of random mutations rather than biological differences between animal and human susceptibility. A multidisciplinary workshop responding to this challenge convened at The Jackson Laboratory in Bar Harbor, Maine. The purpose of the workshop was to assess the applicability of an emerging repertoire of genomic technologies to studies of human germ‐cell mutagenesis. Workshop participants recommended large‐scale human germ‐cell mutation studies be conducted using samples from donors with high‐dose exposures, such as cancer survivors. Within this high‐risk cohort, parents and children could be evaluated for heritable changes in (a) DNA sequence and chromosomal structure, (b) repeat sequences and minisatellites, and (c) global gene expression profiles and pathways. Participants also advocated the establishment of a bio‐bank of human tissue samples from donors with well‐characterized exposure, including medical and reproductive histories. This mutational resource could support large‐scale, multiple‐endpoint studies. Additional studies could involve the examination of transgenerational effects associated with changes in imprinting and methylation patterns, nucleotide repeats, and mitochondrial DNA mutations. The further development of animal models and the integration of these with human studies are necessary to provide molecular insights into the mechanisms of germ‐cell mutations and to identify prevention strategies. Furthermore, scientific specialty groups should be convened to review and prioritize the evidence for germ‐cell mutagenicity from common environmental, occupational, medical, and lifestyle exposures. Workshop attendees agreed on the need for a full‐scale assault to address key fundamental questions in human germ‐cell environmental mutagenesis. These include, but are not limited to, the following: Do human germ‐cell mutagens exist? What are the risks to future generations? Are some parents at higher risk than others for acquiring and transmitting germ‐cell mutations? Obtaining answers to these, and other critical questions, will require strong support from relevant funding agencies, in addition to the engagement of scientists outside the fields of genomics and germ‐cell mutagenesis. Environ. Mol. Mutagen., 2007. Published 2007 Wiley‐Liss, Inc.
- Open Access
- 30 June 2004
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 81 (2) , 512-517
Mitochondrial Damage Revealed by Morphometric and Semiquantitative Analysis of Mouse Pup Cardiomyocytes Following in Utero and Postnatal Exposure to Zidovudine and Lamivudine
Zidovudine (ZDV), an antiretroviral drug used alone or in combination with other antiretroviral agents to treat HIV-infected pregnant women and their newborn infants, effectively reduces mother-to-child transmission of the virus. That myopathy and cardiomyopathy, related to mitochondrial damage, develop in some adults chronically treated with ZDV has long been known; recently, reports have suggested that similar adverse effects may occur in some infants exposed perinatally. Using a mouse model of human neonatal exposure, we treated pregnant CD-1 mice twice daily with doses of 75 mg/kg ZDV plus 37.5 mg/kg lamivudine throughout gestation and lactation; pups were exposed by direct gavage beginning postnatal day (PND) 4 and sacrificed on PND 28. Hearts were removed rapidly, and ventricles were processed for electron microscopy. Morphometric and semiquantitative morphological analyses were performed on three micrographs from each of three blocks from each of three females and three males from the control and treated groups. Treated mice showed significant increases in the mean area and decreases in the mean number of cardiomyocytic mitochondria compared to controls. We observed clusters of damaged mitochondria more frequently in treated animals than in controls; damage included fragmentation and loss of cristae. These results, demonstrating alterations in cardiomyocytic mitochondria of mice exposed in utero and postnatally, may model cardiac damage reported in human infants similarly exposed to ZDV. Critical insights derived from animal-model data like these may be used to mitigate risks to thousands of human infants receiving essential lifesaving therapy with antiretroviral drugs.
- 30 June 2004
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 81 (2) , 512-517
Open AccessMitochondrial Damage Revealed by Morphometric and Semiquantitative Analysis of Mouse Pup Cardiomyocytes Following in Utero and Postnatal Exposure to Zidovudine and Lamivudine
Zidovudine (ZDV), an antiretroviral drug used alone or in combination with other antiretroviral agents to treat HIV-infected pregnant women and their newborn infants, effectively reduces mother-to-child transmission of the virus. That myopathy and cardiomyopathy, related to mitochondrial damage, develop in some adults chronically treated with ZDV has long been known; recently, reports have suggested that similar adverse effects may occur in some infants exposed perinatally. Using a mouse model of human neonatal exposure, we treated pregnant CD-1 mice twice daily with doses of 75 mg/kg ZDV plus 37.5 mg/kg lamivudine throughout gestation and lactation; pups were exposed by direct gavage beginning postnatal day (PND) 4 and sacrificed on PND 28. Hearts were removed rapidly, and ventricles were processed for electron microscopy. Morphometric and semiquantitative morphological analyses were performed on three micrographs from each of three blocks from each of three females and three males from the control and treated groups. Treated mice showed significant increases in the mean area and decreases in the mean number of cardiomyocytic mitochondria compared to controls. We observed clusters of damaged mitochondria more frequently in treated animals than in controls; damage included fragmentation and loss of cristae. These results, demonstrating alterations in cardiomyocytic mitochondria of mice exposed in utero and postnatally, may model cardiac damage reported in human infants similarly exposed to ZDV. Critical insights derived from animal-model data like these may be used to mitigate risks to thousands of human infants receiving essential lifesaving therapy with antiretroviral drugs.
- 16 January 2004
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 43 (1) , 3-9
Genetic damage detected in CD‐1 mouse pups exposed perinatally to 3′‐azido‐3′‐deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage
Human immunodeficiency virus (HIV)‐infected pregnant women are administered nucleoside‐analogue antiretrovirals to reduce maternal‐infant viral transmission. The current protocol recommends treating newborns for 6 additional weeks postpartum. The treatment is effective, but the risk of drug‐induced chromosomal damage in neonates remains undefined. We used a mouse model to investigate this concern. In a multigeneration reproductive toxicity study, female CD‐1 mice received 3′‐azido‐3′‐deoxythymidine (AZT) and dideoxyinosine (ddI) (50/250, 75/375, 150/750 mg/kg/day AZT/ddI) by gavage twice daily in equal fractions beginning prior to mating and continuing throughout gestation and lactation. Direct pup dosing (same regimen) began on postnatal day (PND) 4. Peripheral blood erythrocytes of male pups were screened for micronuclei, markers of chromosomal damage, on PNDs 1, 4, 8, and 21. Extraordinary increases in micronucleated cells were noted in pups for each treatment group at each sampling time; treated dams exhibited smaller yet significant increases in micronucleated erythrocytes. The frequencies of micronucleated cells in untreated pups were higher than in the untreated dams, and all pups had markedly elevated levels of circulating reticulocytes compared to dams. These observations suggest that fetal and neonatal mouse hematopoietic precursor cells have heightened sensitivity to genotoxic agents, perhaps due to rapid cell proliferation during the perinatal period of development. The amount of genetic damage observed in treated pups raises concern for the potential of similar damage in humans. Investigations of chromosomal integrity in exposed newborns and children are recommended. Environ. Mol. Mutagen. 43:3–9, 2004.
- 16 January 2004
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 43 (1) , 3-9
Genetic damage detected in CD‐1 mouse pups exposed perinatally to 3′‐azido‐3′‐deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage
Human immunodeficiency virus (HIV)‐infected pregnant women are administered nucleoside‐analogue antiretrovirals to reduce maternal‐infant viral transmission. The current protocol recommends treating newborns for 6 additional weeks postpartum. The treatment is effective, but the risk of drug‐induced chromosomal damage in neonates remains undefined. We used a mouse model to investigate this concern. In a multigeneration reproductive toxicity study, female CD‐1 mice received 3′‐azido‐3′‐deoxythymidine (AZT) and dideoxyinosine (ddI) (50/250, 75/375, 150/750 mg/kg/day AZT/ddI) by gavage twice daily in equal fractions beginning prior to mating and continuing throughout gestation and lactation. Direct pup dosing (same regimen) began on postnatal day (PND) 4. Peripheral blood erythrocytes of male pups were screened for micronuclei, markers of chromosomal damage, on PNDs 1, 4, 8, and 21. Extraordinary increases in micronucleated cells were noted in pups for each treatment group at each sampling time; treated dams exhibited smaller yet significant increases in micronucleated erythrocytes. The frequencies of micronucleated cells in untreated pups were higher than in the untreated dams, and all pups had markedly elevated levels of circulating reticulocytes compared to dams. These observations suggest that fetal and neonatal mouse hematopoietic precursor cells have heightened sensitivity to genotoxic agents, perhaps due to rapid cell proliferation during the perinatal period of development. The amount of genetic damage observed in treated pups raises concern for the potential of similar damage in humans. Investigations of chromosomal integrity in exposed newborns and children are recommended. Environ. Mol. Mutagen. 43:3–9, 2004.
- 25 February 2003
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 41 (2) , 111-120
Mouse bone marrow micronucleus test results do not predict the germ cell mutagenicity of N-hydroxymethylacrylamide in the mouse dominant lethal assay
- 25 February 2003
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 41 (2) , 111-120
Mouse bone marrow micronucleus test results do not predict the germ cell mutagenicity of N-hydroxymethylacrylamide in the mouse dominant lethal assay
- 1 January 2003
- Published by Springer Nature
- Vol. 518, 1-9
Female-specific reproductive toxicites following preconception exposure to xenobiotics
There are only a few testing strategies directed specifically at female reproductive toxicity. (Generoso et al, 1971; Generoso and Cosgove, 1973; Bishop et al., 1997). There are some elegant molecular studies of female germ cell and reproductive biology (Eichenlaub-Ritter, et al., 1988; Albertini, et al., 2001; Hunt et al, 1995) but few, if any, of these investigations involve toxicological perspectives. Future research efforts in female, as well as male, reproductive toxicology would benefit greatly by enhanced integration of knowledge and methodology from molecular developmental and cell biology. In this chapter, I will review some basic reproductive biology, emphasizing differences between females and males, describe tests for female reproductive toxicology used by the National Toxicology Program (NTP) at NIEHS, summarize NTP test data and discuss some of the dogmas of germ cell mutagenesis that have recently been dispelled by these data.
- 1 January 2003
- Published by Springer Nature
- Vol. 518, 1-9
Female-specific reproductive toxicites following preconception exposure to xenobiotics
There are only a few testing strategies directed specifically at female reproductive toxicity. (Generoso et al, 1971; Generoso and Cosgove, 1973; Bishop et al., 1997). There are some elegant molecular studies of female germ cell and reproductive biology (Eichenlaub-Ritter, et al., 1988; Albertini, et al., 2001; Hunt et al, 1995) but few, if any, of these investigations involve toxicological perspectives. Future research efforts in female, as well as male, reproductive toxicology would benefit greatly by enhanced integration of knowledge and methodology from molecular developmental and cell biology. In this chapter, I will review some basic reproductive biology, emphasizing differences between females and males, describe tests for female reproductive toxicology used by the National Toxicology Program (NTP) at NIEHS, summarize NTP test data and discuss some of the dogmas of germ cell mutagenesis that have recently been dispelled by these data.
- Open Access
- 15 July 2001
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 184 (2) , 127-135
Antiretroviral Therapy Effects on Genetic and Morphologic End Points in Lymphocytes and Sperm of Men with Human Immunodeficiency Virus Infection
Many human immunodeficiency virus (HIV)–infected persons receive prolonged treatment with DNA-reactive antiretroviral drugs. A prospective study was conducted of 26 HIV-infected men who provided samples before treatment and at multiple times after beginning treatment, to investigate effects of antiretrovirals on lymphocyte and sperm chromosomes and semen quality. Several antiretroviral regimens, all including a nucleoside component, were used. Lymphocyte metaphase analysis and sperm fluorescence in situ hybridization were used for cytogenetic studies. Semen analyses included conventional parameters (volume, concentration, viability, motility, and morphology). No significant effects on cytogenetic parameters, semen volume, or sperm concentration were detected. However, there were significant improvements in sperm motility for men with study entry CD4 cell counts >200 cells/mm3, sperm morphology for men with entry CD4 cell counts ⩽200 cells/mm3, and the percentage of viable sperm in both groups. These findings suggest that nucleoside-containing antiretrovirals administered via recommended protocols do not induce chromosomal changes in lymphocytes or sperm but may produce improvements in semen quality
- 15 July 2001
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 184 (2) , 127-135
Open AccessAntiretroviral Therapy Effects on Genetic and Morphologic End Points in Lymphocytes and Sperm of Men with Human Immunodeficiency Virus Infection
Many human immunodeficiency virus (HIV)–infected persons receive prolonged treatment with DNA-reactive antiretroviral drugs. A prospective study was conducted of 26 HIV-infected men who provided samples before treatment and at multiple times after beginning treatment, to investigate effects of antiretrovirals on lymphocyte and sperm chromosomes and semen quality. Several antiretroviral regimens, all including a nucleoside component, were used. Lymphocyte metaphase analysis and sperm fluorescence in situ hybridization were used for cytogenetic studies. Semen analyses included conventional parameters (volume, concentration, viability, motility, and morphology). No significant effects on cytogenetic parameters, semen volume, or sperm concentration were detected. However, there were significant improvements in sperm motility for men with study entry CD4 cell counts >200 cells/mm3, sperm morphology for men with entry CD4 cell counts ⩽200 cells/mm3, and the percentage of viable sperm in both groups. These findings suggest that nucleoside-containing antiretrovirals administered via recommended protocols do not induce chromosomal changes in lymphocytes or sperm but may produce improvements in semen quality
- Open Access
- 1 December 1997
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 396 (1-2) , 9-43
Genetic toxicities of human teratogens
- 1 December 1997
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 396 (1-2) , 9-43
Open AccessGenetic toxicities of human teratogens